Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 5
2020 10
2021 16
2022 14
2023 19
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, Fukuokaya W, Shim SR, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Pallauf M, Pradere B, Kimura T, Egawa S, Shariat SF. Yanagisawa T, et al. Among authors: fukuokaya w. Eur Urol. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19. Eur Urol. 2022. PMID: 35995644 Free article. Review.
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Ohno T, Nakamori K, Maenosono R, Nishimura K, Yamazaki S, Uchimoto T, Yanagisawa T, Mori K, Urabe F, Tsuzuki S, Iwatani K, Yamamoto S, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Azuma H. Tsujino T, et al. Among authors: fukuokaya w. Cancer Med. 2023 Oct;12(19):19414-19422. doi: 10.1002/cam4.6536. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37706578 Free PMC article.
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T, Rajwa P, Kawada T, Mori K, Fukuokaya W, Petrov P, Quhal F, Laukhtina E, von Deimling M, Bianchi A, Majdoub M, Pradere B, Kramer G, Kimura T, Shariat SF. Yanagisawa T, et al. Among authors: fukuokaya w. J Urol. 2023 Sep;210(3):416-429. doi: 10.1097/JU.0000000000003594. Epub 2023 Jun 20. J Urol. 2023. PMID: 37339479 Review.
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
Mori K, Yanagisawa T, Fukuokaya W, Iwatani K, Matsukawa A, Katayama S, Pradere B, Laukhtina E, Rajwa P, Moschini M, Albisinni S, Krajewski W, Cimadamore A, Del Giudice F, Teoh J, Urabe F, Kimura S, Murakami M, Tsuzuki S, Miki J, Miki K, Shariat SF, Kimura T; European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Mori K, et al. Among authors: fukuokaya w. Int J Urol. 2024 Jan;31(1):25-31. doi: 10.1111/iju.15319. Epub 2023 Oct 15. Int J Urol. 2024. PMID: 37840031 Review.
Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.
Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Bekku K, Laukhtina E, Rajwa P, Quhal F, Pradere B, Fukuokaya W, Iwatani K, Murakami M, Bensalah K, Grünwald V, Schmidinger M, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: fukuokaya w. Cancer Immunol Immunother. 2024 Jan 30;73(2):38. doi: 10.1007/s00262-023-03621-1. Cancer Immunol Immunother. 2024. PMID: 38289361 Free PMC article. Review.
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: fukuokaya w. Prostate. 2023 May;83(6):563-571. doi: 10.1002/pros.24488. Epub 2023 Jan 20. Prostate. 2023. PMID: 36661102
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H. Uchimoto T, et al. Among authors: fukuokaya w. BJU Int. 2023 Apr;131(4):477-485. doi: 10.1111/bju.15893. Epub 2022 Sep 26. BJU Int. 2023. PMID: 36098556
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.
Fukuokaya W, Mori K, Yanagisawa T, Akazawa K, Shimomura T, Kimura T. Fukuokaya W, et al. Prostate Cancer Prostatic Dis. 2023 Jul 18. doi: 10.1038/s41391-023-00695-x. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37464102
62 results